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ABSTRACT 
Assay interference caused by small molecules continues to pose a significant challenge for early 
drug discovery. A number of rule-based and similarity-based approaches have been derived that 
allow the flagging of potentially “badly behaving compounds”, “bad actors” or “nuisance 
compounds”. These compounds are typically aggregators, reactive compounds and/or pan-assay 
interference compounds (PAINS), and many of them are frequent hitters. Hit Dexter is a recently 
introduced machine learning approach that predicts frequent hitters independent of the 
underlying physicochemical mechanisms (including also the binding of compounds based on 
"privileged scaffolds" to multiple binding sites). Here we report on the development of a second 
generation of machine learning models which now cover both primary screening assays and 
confirmatory dose-response assays. Protein sequence clustering was newly introduced to 
minimize the overrepresentation of structurally and functionally related proteins. The models 
correctly classified compounds of large independent test sets as (highly) promiscuous or non-
promiscuous with Matthews correlation coefficient (MCC) values of up to 0.64 and area under 
the receiver operating characteristic curve (AUC) values of up to 0.96. The models were also 
utilized to characterize sets of compounds with specific biological and physicochemical 
properties, such as dark chemical matter, aggregators, compounds from a high-throughput 
screening library, drug-like compounds, approved drugs, potential PAINS and natural products. 
Among the most interesting outcomes is that the new Hit Dexter models predict the presence of 
large fractions of (highly) promiscuous compounds among approved drugs. Importantly, 
predictions of the individual Hit Dexter models are generally in good agreement and consistent 
with those of Badapple, an established statistical model for the prediction of frequent hitters. The 
new Hit Dexter 2.0 web service, available at http://hitdexter2.zbh.uni-hamburg.de, not only 
provides user-friendly access to all machine learning models presented in this work but also to 
similarity-based methods for the prediction of aggregators and dark chemical matter as well as a 
comprehensive collection of available rule sets for flagging frequent hitters and compounds 
including undesired substructures. 
INTRODUCTION 
Biochemical assays are a core component of early drug discovery.1–3 Some small molecules 
however can pose significant challenges to biochemical assays as they may trigger false 
outcomes. Whereas false negative results may lead to a loss of valuable bioactive compounds, 
false positive outcomes can, if they remain undetected, tie up and consume significant resources 
and time without prospect of success. In the worst case, these “badly behaving compounds”, 
“bad actors” or “nuisance compounds” get reported as bioactive compounds and pollute the 
medicinal chemistry and chemical biology literature. Once published, invalid assay outcomes 
may propagate and trigger follow-up studies based on false grounds, which hampers the global 
drug discovery effort. 
Nuisance compounds (Figure 1) include compounds that can form colloidal aggregates,4,5 
compounds with reactive groups,6 and pan assay interference compounds (PAINS).7 Note that 
the PAINS substructures by design do not cover aggregators because they were derived from the 
outcomes of high-throughput screening campaigns run in the presence of a detergent and casein 
in order to minimize phenomena related to aggregate formation. They also do not cover many 
types of reactive compounds because compounds with reactive functional groups had been 
removed from the screening library prior to assaying.7 
The different types of badly behaving compounds discussed so far involve no definite assertions 
about the frequency by which they cause assay interference. Rather than interfering with all 
different kinds of assays they trigger false outcomes only under specific (and by far not all) 
conditions. However, a tendency of badly behaving compounds to have higher hit rates is 
apparent. 
Compounds for which a higher than expected hit rate is recorded in historical assay data are 
referred to as “frequent hitters”.8 Many of these compounds are aggregators, reactive compounds 
or PAINS, but importantly, a significant proportion of frequent hitters are true promiscuous 
compounds. True promiscuity is often related to “privileged scaffolds”9 or “master key 
compounds”,10 which have the ability to bind to multiple binding sites. True promiscuous 
compounds are not necessarily nuisance compounds. In fact, they can be valuable in the context 
of drug repurposing and polypharmacology.11,12 
Computational methods for predicting nuisance compounds and frequent hitters are still in an 
early stage of development.13 The most established approaches for identifying problematic 
compounds are rule-based methods, which flag compounds containing substructures that have 
been linked to assay interference. In recent years, the 480 patterns encoding substructures 
derived from PAINS have become not only one of the best known but also one of the most 
misused rule sets in medicinal chemistry. All too often, the limitations of the PAINS concept, 
most of which have been pointed out clearly by its inventors, are not paid the necessary 
attention.14,15 Further approaches for the prediction of nuisance compounds and frequent hitters 
include similarity-based approaches, statistical and machine learning approaches, an overview of 
which is provided in ref 13. 
An important statistical approach for the prediction of frequent hitters is Badapple,16 which 
performs a hierarchical scaffold analysis to derive a promiscuity score (“pScore”). The pScore 
corresponds to the likelihood of a compound based on a specific scaffold being promiscuous. 
Badapple was derived from a large public data set of more than 430k compounds measured in a 
total of more than 800 different assays.  
We recently reported two machine learning models for the prediction of frequent hitters which 
are accessible via a free web service called “Hit Dexter”.17 Hit Dexter was developed with the 
idea of creating a reliable model for the prediction of frequent hitters independent of the 
underlying physicochemical mechanisms (including also the binding of compounds based on 
"privileged scaffolds" to multiple binding sites). Such a model could advice scientists for which 
compounds to exercise extra caution with positive assay readouts. The initial Hit Dexter models 
were trained on more than 235k compounds measured in at least 50 different confirmatory dose-
response assays (CDRAs). They reached a high level of accuracy on independent test data, with 
Matthews correlation coefficients18 (MCCs) of up to 0.67 and area under the receiver operating 
characteristic curve (AUC) values of up to 0.96. 
Here we report on the development of a second generation of machine learning models for the 
prediction of frequent hitters, which are accessible via the new Hit Dexter 2.0 web service.19 The 
models are a result of several major refinements and extensions of the data collection, data 
processing and modeling procedures. For example, a clustering approach was introduced in order 
to avoid an overrepresentation of structurally and functionally related proteins such as protein 
kinases. Hit Dexter 2.0 also includes models trained on data measured with primary screening 
assays (PSAs). In contrast to CDRAs, PSAs are primarily high-throughput screening assays 
measuring single-dose inhibition. The inclusion of these models in Hit Dexter 2.0 will allow a 
better representation of assays employed for primary screening. 
In addition to method and model refinement, we also report on comprehensive tests of Hit 
Dexter 2.0 with various types of compounds, including dark chemical matter (DCM),20 approved 
drugs and natural products. Last but not least, we present a direct comparison of Hit Dexter 2.0 
with Badapple and introduce the new Hit Dexter 2.0 web service. 
 
Figure 1. Schematic overview of key concepts and terms used in the context of assay 
interference and small-molecule drug discovery. Note that by design PAINS exclude aggregators 
and many types of reactive compounds. However, overlaps between the different types of 
compounds other than those depicted in this scheme certainly exist. 
RESULTS AND DISCUSSION 
Data Set Compilation and Analysis 
Two large data sets were compiled from PubChem Bioassay,21,22 one consisting of 803 898 
compounds measured in 931 PSAs and the other one consisting of 468 258 compounds measured 
in 2273 CDRAs. During data preprocessing, filtering in particular, 20 921 and 18 003 
compounds were removed from the PSA and CDRA data sets, respectively (Table 1).  
 
Table 1. Number of Compounds Removed During Filtering and Quality Checks. 
Reason for removal PSA data set [cpds] CDRA data set [cpds] 
Invalid SMILES notation 1 3 
Salt filter with ambiguous 
outcomea 
770 231 
Molecular weight outside the 
range of 200 to 900 Da 
11 231 10 815 
Elements other than H, B, C, 
N, O, F, Si, P, S, Cl, Se, Br 
and I 
116 175 
Duplicate moleculesb 8460 5171 
Rejected during quality 
checksc 
343 1608 
Sum 20 921 18 003 
 
a Multi-component compounds for which the main component could not be unequivocally 
defined (see Methods and ref 17 for detail). 
b Identified based on canonicalized SMILES. Associated data were merged as outlined in ref 17. 
This led to the effective reduction of the number of compounds as reported in the table. 
c Compounds with conflicting data (e.g. activity data). See Methods and ref 17 for detail). 
 
Following this procedure, the proteins covered by the PSA and CDRA data sets were clustered 
based on sequence similarity: The 429 proteins covered by the PSA data set were assigned to 388 
unique protein clusters, and the 712 proteins covered by the CDRA data set were assigned to 537 
unique protein clusters (see Methods for detail).  
The definition of whether a compound is (highly) promiscuous or not is based on the active-to-
tested ratio (ATR), which is calculated according to Equation 1: 
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where A is the number of protein clusters for which a compound was measured as active on at 
least one protein of that cluster, and T is the total number of protein clusters a compound was 
measured on. 
The ideal data set to derive ATRs from would consist of a large number of compounds measured 
on a large number of protein clusters. Obviously, with the available data a compromise needs to 
be found between the number of instances available for training and testing the models (i.e. size 
of the data set in terms of the number of compounds) and the minimum number of protein 
clusters for which activity data are recorded for the individual compounds. 
Figure 2 shows the relationship between data set size and the minimum number of protein 
clusters for which assay results have been recorded. For example, the processed data set includes 
362k compounds which have been measured with PSAs representing at least 50 different protein 
clusters. Likewise, 327k compounds are represented by the respective data collected from 
CDRAs. One of the most obvious differences between the PSA and CDRA data sets is that for 
the vast majority of compounds of the PSA data set measured data are available for 150 and 
more protein clusters, whereas for the CDRA data set a steep decline in the number of 
compounds for which measured data are available for 70 and more protein clusters is observed. 
We explored the use of data sets containing all compounds for which bioactivity data has been 
recorded for at least 20, 50 and (only for PSAs) 100 protein clusters (data not shown). In 
agreement with previous results,17 we found the data sets containing all compounds for which 
bioactivity data has been recorded for at least 50 protein clusters to be highly diverse and most 
suitable for modeling. We refer to these data sets as the PSA50 and CDRA50 data sets. 
 
Figure 2. Data set size (number of compounds) as a function of the minimum number of protein 
clusters for which measured data are available. The rectangles mark the PSA20/CDRA20, 
PSA50/CDRA50 and PSA100/CDRA100 data sets. 
 
Next, all compounds were assigned a promiscuity label based on their ATR: “NP” for non-
promiscuous compounds, “P” for promiscuous compounds and “HP” for highly promiscuous 
compounds. Note that, according to the definitions of promiscuity summarized in Table 2, highly 
promiscuous compounds are a subset of promiscuous compounds. 
Suitable cutoffs for the assignment of promiscuity labels were calculated for the PSA50 and 
CDRA50 data sets according to the definitions derived as part of our previous work (recited in 
Table 2, column “threshold definition”).17 According to these definitions, any compounds with 
an ATR greater than 0.024 for PSAs and 0.043 for CDRAs were labeled promiscuous, 
accounting for 11% and 13% of all compounds, respectively. These proportions of promiscuous 
compounds are in good agreement e.g. with the findings of a recent study from 
GlaxoSmithKline, which reported a fraction of 13% of all compounds as "noisy",23 and higher 
than the averaged incidence of frequent hitters reported for the AstraZeneca screening library 
(which is 6%).24 The mean ATRs for the PSA and CDRA data sets were 0.008 and 0.015, 
respectively (see Table 2 for more detail). These mean ATRs correspond well to the findings of 
other studies, such as that on the AstraZeneca compound collection, which reported an overall hit 
rate of 1.53%.24  
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a Derived as part of our previous work.17 Compounds with ATRs between ATRmean and ATRmean 
+ 1σ were not assigned a promiscuity label and removed from all data sets. 
b ATR threshold values calculated for the individual data sets according to the ATR threshold 
definition. 
c Independent test set obtained by random split of the curated data set prior to model 
development. 
d Standard deviation. 
 
CDRAs tend to have higher hit rates than PSAs. This is observed in the ATR distributions 
reported in Figure 3 and also reflected in the higher mean ATR for CDRAs (Table 2). The 
differences in hit rates can be explained by the fact that CDRAs are often used to measure 
compounds which have previously been reported as active by a PSA and are hence more likely to 
also show activity in CDRAs than a random set of screening compounds.  
 
 
Figure 3. ATR distributions calculated for the (A) PSA50 and (B) CDRA50 data sets. The 
vertical lines mark the cutoffs applied for the assignment of promiscuity labels. Any compounds 
below the green line were labeled “NP”, any above the yellow line “P”, and any above the red 
line “HP”. 
  
Comparison of the Chemical Space of the PSA and CDRA Data Sets 
The chemical space of the individual data sets used for modeling was determined and compared 
using (i) principal component analysis (PCA) on 44 physically meaningful 2D descriptors 
computed with MOE25 (listed in Table S1 of ref. 17) and (ii) pairwise similarity analysis based on 
the Tanimoto coefficient calculated from Morgan2 fingerprints.26,27 
In a first experiment, we analyzed whether the reduction of the PSA and CDRA data sets to 
subsets of compounds annotated with measured data for at least 50 protein clusters leads to a 
substantial loss of coverage. As shown by the PCA scatter plots and histograms reported in 
Figure 4, the chemical space of compounds covered by the PSA50 and CDRA50 data sets is–to a 
large extent–comparable with that of the PSA0 and CDRA0 data sets, respectively. Only about 
11% of all compounds of the PSA0 data set and about 9% of all compounds of the CDRA0 data 
set have a maximum Tanimoto coefficient of less than 0.5 measured against any compounds 
present in the PSA50 and CDRA50 data sets, respectively. In other words, this means that by 
constraining the data used for model development to compounds for which measured data has 
been recorded for at least 50 protein clusters does not lead to a substantial reduction of chemical 
space coverage as compared to the complete (processed) PubChem Bioassay data sets. 
 
Figure 4. Comparison of the chemical space of the (A, B) PSA0 and PSA50 data sets and (C, D) 
CDRA0 and CDRA50 data sets. The PCA scatter plots are based on the first against the second 
component and derived from 44 physicochemically meaningful 2D descriptors calculated with 
MOE (see Table S1 in ref. 17). PCA was performed on the full dataset. For the sake of clarity, 
only a randomly selected 1% of all data points are shown. The axis labels report the percentage 
of the total variance explained by the respective principal component. The histograms show the 
proportion of compounds of the (B) PSA0 or (D) CDRA0 data set represented by compounds of 
the (B) PSA50 or (D) CDRA50 data set at a given minimum similarity (Tanimoto coefficient 
calculated from Morgan2 fingerprints). 
 
Following the same protocol, we also compared the chemical space covered by the PSA50 and 
CDRA50 data sets. As shown in Figure 5A and D, no substantial differences in coverage 
between the two data sets are apparent from the PCA and pairwise similarity analysis. Last but 
not least we compared the PSA50 and CDRA50 data sets to the complete ChEMBL database.28,29 
The ChEMBL database was prepared following the identical data preprocessing protocol 
(without considering any biological data) and consists of about 1.5 million compounds. From 
this comparison it can be seen that chemical space of the ChEMBL database is wider than that of 
the PSA50 and CDRA50 data sets (Figure 5B, C, E and F). This is an expected result, since the 
ChEMBL database contains substantially more compounds from a large number of diverse 
sources. Nevertheless, the plots also show that approximately 50% of all ChEMBL compounds 
are well represented by the PSA50 and CDRA50 data sets. 
Model Development 
Prior to model development, the PSA50 and CDRA50 data sets were randomly split into a 
training and a test set with a ratio of 9:1. In contrast to our previous work,17 an additional data 
preprocessing step was implemented which checks for the presence of any compounds with 
distinct canonicalized SMILES but identical Morgan2 fingerprints (as in the case of 
stereoisomers, for example) because this can lead to inconsistent predictions. In order to address 
these issues, any instances with identical Morgan2 fingerprints were merged if their promiscuity 
labels were identical. If their labels differed, all instances with identical Morgan2 fingerprints 
were removed from the training data. Table 3 lists the number of compounds removed from the 
training and test sets as part of this process. 
For assays of both screening stages (i.e. PSAs and CDRAs), two binary classifiers were 
developed: one to distinguish promiscuous from non-promiscuous compounds (P-NP classifier) 
and another one to distinguish highly promiscuous from non-promiscuous compounds (HP-NP 
classifier). An overview of the size of the training and test set is reported in Table 2. 
As a first step in the model building process, the most suitable machine learning algorithm and 
descriptor set were identified. In addition to the extra tree classifiers (ETC) and random forest 
classifiers (RFC) explored in our previous work,17 we also tested several meta classifiers such as 
the AdaBoost Classifier30,31 and Bagging Classifier,32,33 both in combination with the ETC and 
RFC. With respect to descriptors, we explored all 206 2D descriptors available in MOE, 
Morgan2 fingerprints (1024 bit), and MACCS keys (166 bits). 
 
 
Figure 5. Comparison of the chemical space of the PSA50, CDRA50 and ChEMBL data sets in 
the (A, B, C) MOE 2D descriptor space and (D, E, F) Morgan2 fingerprint space. The PCAs 
were performed on the full datasets. For the sake of clarity, only a randomly selected 1% of all 
data points are shown. The axis labels report the percentage of the total variance explained by the 
respective principal component. The histograms show the proportion of compounds of the 
specified data sets represented by the (D, E) PSA50 and (D, F) CDRA50 data at a given 
minimum similarity (Tanimoto coefficient calculated from Morgan2 fingerprints). 
 
Table 3. Number of Compounds Filtered Due to Duplicate Morgan2 Fingerprints. 
Data set 
No. of compounds merged 
due to identical fingerprints 
and promiscuity labels 
No. of compounds with 
identical fingerprints 
removed due to contradicting 
promiscuity labels 
PSA50 training set 2 522 303 
PSA50 test set 41 8 
CDRA50 training set 1 664 281 
CDRA50 test set 26 4 
 
The various combinations of machine learning algorithms and descriptors were tested with 10-
fold cross-validation (see Methods for more detail). The performance of the individual classifiers 
was compared based on the MCC, which quantifies the correlation between the predictions and 
their true value by taking into account the true positive, false positive, true negative and true 
positive predictions. MCC values range from -1 to +1, where a value of +1 indicates perfect 
prediction, a value of 0 a performance equal to random prediction, and a value of -1 total 
disagreement of the prediction. In addition, we generated receiver operating characteristic (ROC) 
curves and calculated the area under the ROC curves (AUCs). By considering these three 
components, a solid understanding of the goodness of the models can be obtained: Whereas the 
MCC quantifies the capability of a model to correctly classify a compound of interest, ROC 
curves and (to some extent also) AUC values quantify a model’s ability to identify (highly) 
promiscuous compounds by assigning them high probabilities as compared to non-promiscuous 
compounds (i.e., ranking (highly) promiscuous compounds early in a list). 
For all data sets the best performance during 10-fold cross-validation was obtained by ETCs in 
combination with Morgan2 fingerprints (MCC values between 0.56 and 0.58). These 
observations are consistent with the observations made during our previous work.17 
Following these experiments, the hyperparameters (Table 4) for the ETCs (in combination with 
Morgan2 fingerprints) were optimized, again with 10-fold cross-validation and with MCC as 
performance measure. Optimization of the hyperparameters did not yield substantial 
improvements of the models. The most suitable settings for the number of estimators and the 
maximum fraction of features considered per split were 100 and 0.2, respectively. Classifiers 
using these hyperparameters obtained MCC values between 0.57 and 0.60 and AUC values 
between 0.91 and 0.96 during 10-fold cross-validation (Figure 6). The final models (with 
optimized parameters) were built on the complete training sets balanced with the synthetic 
minority oversampling technique (SMOTE).34 
Table 4. Hyperparameters Optimized by Grid Search.a 
Parameter Option 
Number of estimators 
(estimators)b 
10c,50,100,150,200,250,300,400,500,600 
Maximum fraction of features 
considered per split 
(max_features)b 
sqrtc, 0.2, 0.4, 0.6, 0.8, noned 
a Bold numbers indicate settings used for the production of the final models. 
b Parameter name in the scikit-learn35 implementation. 
c Default value. 
d All features are used. 
 
 
Figure 6. ROC curves obtained during 10-fold cross-validation for the selected models (i.e. ETC 
in combination with Morgan2 fingerprints; n_estimators = 100; max_features = 0.2). (A) HP-NP 
classifier for PSAs, (B) P-NP classifier for PSAs, (C) HP-NP classifier for CDRAs, (D) P-NP 
classifier for CDRAs. 
 
Model Evaluation on Independent Test Data 
The final models (ETC; Morgan2 fingerprints; SMOTE for balancing the training data; 
n_estimators = 100; max_features = 0.2), referred to as Hit Dexter 2.0 models, were tested on an 
independent test set (Table 2) derived by random split of the preprocessed PSA50/CDRA50 data 
sets prior to model building. The MCC values obtained by the four classifiers (i.e. HP-NP and P-
NP classifiers, trained on PSA or CDRA data) for the independent test set was between 0.60 and 
0.64 (Figure 7A), whereas their AUC values ranged from 0.91 to 0.96. Both HP-NP classifiers 
performed on average slightly better than the P-NP classifiers. This is expected because the 
margin between the cutoffs utilized to assign compounds to either of the two promiscuity classes 
is larger for the HP-NP classifier.  
The robustness of the Hit Dexter 2.0 models was further probed by iteratively removing 
compounds from the test set that are similar to any of the compounds in the training data. More 
specifically, the maximum allowed similarity between the compounds of the test set and any 
compounds in the training set (measured as Tanimoto coefficient calculated from Morgan2 
fingerprints) was reduced by 0.02 during each iteration (Figure 8). For example, for the subset of 
test compounds with a maximum Tanimoto coefficient of 0.8, MCC values of 0.55 to 0.58 were 
obtained, whereas AUC values were between 0.90 and 0.95 (Figure 7B). For the subset of test 
compounds with a maximum Tanimoto coefficient of 0.7, MCC values were between 0.44 and 
0.50, and AUC values between 0.87 and 0.92 (Figure 7C). Decent performance was observed for 
subsets of test compounds with a maximum Tanimoto coefficient as low as 0.6 (MCC values 
between 0.34 and 0.42; AUC values between 0.82 and 0.88). Overall, the MCC values obtained 
for the initial Hit Dexter models17 are slightly higher than those obtained for Hit Dexter 2.0. This 
may be a result of the protein clustering procedure, as compounds active on several related 
proteins (which therefore may contain characteristic structural patterns that can be more easily 
recognized by machine learning algorithm) may no longer be part of the P (and HP) data set. 
 
 
Figure 7. ROC curves obtained for the four classifiers on the independent test set (A) and 
subsets thereof, consisting of compounds with a maximum Tanimoto coefficient of (B) 0.8 or (C) 




Figure 8. Classification performance (measured as MCC values) as a function of the maximum 
molecular similarity (Tanimoto coefficient calculated from Morgan2 fingerprints) between any 
pair of training and test compounds. 
 
Application of Hit Dexter 2.0 to different data sets 
In order to obtain a better understanding of the scope and limitations of Hit Dexter 2.0, we 
analyzed its predictions for a number of data sets with distinct characteristics:  
 
● The dark chemical matter (DCM) data set:20 a library of compounds which have been 
tested in at least one hundred different biochemical assays and have never shown activity. 
This data set originates from Novartis and PubChem assay data collected for 140k 
compounds (all size indications in this list referring to the unprocessed data sets). 
● The aggregators data set:36 a set of 12.6k compounds known to form colloidal aggregates. 
This library serves as data resource for Aggregator Advisor.37 
● The Enamine HTS Collection:38 Enamine is a leading provider of screening compounds 
and screening blocks. The Enamine HTS collection was selected as a representative 
library widely used in high-throughput screening. It contains 1.9 million compounds. 
● The ChEMBL database:29 a curated chemical database of 1.7 million (mainly) drug-like 
compounds, richly annotated with measured bioactivity data. 
● The approved drugs subset of DrugBank:39 a set of 2158 drugs approved in at least one 
jurisdiction, at some point in time. 
● A “potential PAINS” data set: a subset of 51.7k compounds of the Enamine HTS 
Collection that match PAINS patterns (see Methods for detail). 
● A natural products data set: a comprehensive set of 208k known natural products 
compiled from 18 different sources as part of our previous work.40 
The chemical structures included in these data sets were prepared following the identical 
procedure employed for preprocessing the Hit Dexter 2.0 training data. Any compounds present 
in the training data were removed from the individual data sets. The size of the filtered data sets 
is listed in Table 5. 
In the previous section we showed that Hit Dexter 2.0 performs well on compounds represented 
by at least one instance in the training data with a minimum fingerprint-based Tanimoto 
coefficient of 0.6 (Figure 8). Considering this threshold, a large proportion of synthetic 
compounds is covered well by the training data (Figure S1). Taking the PSA50 training set of the 
P-NP classifier as an example, almost all DCM compounds, more than 80% of all aggregators 
and approximately 60% of all approved drugs are represented by at least one instance in the 
training data with a Tanimoto coefficient of 0.6 or higher. The percentage of compounds from 
ChEMBL and the Enamine HTS collection covered at this level of (minimum) similarity is about 
40%. In contrast to synthetic compounds, only for approximately 15% of all natural products the 
maximum pairwise similarity (measured as Tanimoto coefficient based on Morgan2 fingerprints) 
with all instances of the training data is 0.6 or higher (Figure 9).  
 
Table 5. Agreement of Predictions of the PSA and CDRA Classifiers. 
 
Data set 
No. of cpds 
in the HP-


































DCM 11 116 79 (0.7) 69 (0.6) 26.5 10 944 306 (2.8) 361 (3.3) 19.1 
Aggregators 5786 225 (3.9) 272 (4.7) 34.0 4183 514 (12.3) 596 (14.3) 37.6 
Enamine HTS 
collection 
1 856 964 5883 (0.3) 7961 (0.4) 33.2 1 853 518 31 068 (1.7) 46 190 (2.5) 38.1 
ChEMBL 1 194 343 27 643 (2.3) 26 447 (2.2) 37.0 1 166 478 88527 (7.6) 95 031 (8.2) 46.0 
Approved Drugs 972 48 (4.9) 58 (6.0) 39.5 813 93 (11.4) 102 (12.6) 36.4 
Potential PAINS 49 498 1670 (3.4) 2246 (4.5) 45.9 49 044 4867 (9.9) 6925 (14.1) 50.2 
Natural Products 167 873 8010 (4.8) 7919 (4.7) 36.4 167 557 24 046 (14.4) 22 641 (13.5) 57,0 
BADAPPLE_NP 110 624 1575 (1.4) 1873 (1.7) 32.0 108 620 7239 (6.7) 9853 (9.1) 42.4 
BADAPPLE_P 346 82 (23.7) 87 (25.1) 55.1 330 170 (51.5) 203 (61.5) 69.6 
BADAPPLE_HP 104 53 (51.0) 52 (50.0) 75.0 98 66 (67.4) 70 (71.4) 88.9 
 
 
Figure 9. Example of the distribution of maximum pairwise similarities (Tanimoto coefficient 
calculated from Morgan2 fingerprints) between the training set (in this case, the PSA50 training 
set of the P-NP classifier) and the natural products data set. 
 
Considering the limited prediction accuracy of the classifiers below a Tanimoto coefficient of 0.6 
(Figure 8), the distance to the nearest neighbor(s) in the training data should be closely 
monitored. Therefore, in the following sections, in addition to the percentages of compounds 
referring to the complete, processed data sets, we report in brackets the percentages of 
compounds referring to the respective subsets consisting exclusively of compounds with a 
minimum Tanimoto coefficient of 0.6. In other words, the percentages reported in brackets are 
likely more accurate, but they are based on less-representative subsets. Predictions on the data 
sets listed above are reported in Figures 10 and 11. From the graphs obtained for the DCM data 
set (Figure 10A) it can be seen that any of the four models (i.e. HP-NP and P-NP classifiers, each 
for PSAs and CDRAs) classify at least 96% [96%] of all compounds of the DCM data set as non-
promiscuous (both HP-NP classifiers obtained 99% [99%] correct classifications). This is an 
encouraging result since any of these compounds have been tested in a large number of assays 
and have never shown activity, for which reason they are unlikely frequent hitters (note that all 
reported numbers are based on a decision threshold of 0.5, which is the default value). In contrast 
to the observations made for the DCM data set, a substantial number of compounds of the 
aggregators data set (approximately 15% [18%]) are predicted as promiscuous and 
approximately 4% [5%] as highly promiscuous (with classifiers derived from assays of either 
screening stage (Figure 10B). This again is a plausible result because aggregators are known to 
cause false positive assay readouts under, importantly, specific assay conditions. It is hence 
expected that not all known aggregators will be flagged by Hit Dexter 2.0. The distribution of 
class probabilities among compounds from the Enamine HTS Collection is similar to that of the 
DCM data set (Figure 10C). This suggests that the Enamine HTS Collection is a well-curated 
screening library. For the ChEMBL database, the distributions of class probabilities are located 
somewhere in between those of the DCM data set and the aggregators data set (Figure 10D), 
meaning that there is a relevant fraction of compounds predicted as promiscuous (approximately 
8% [17%]) or highly promiscuous (approximately 2% [6%]). The results obtained for the 
approved drugs data set may seem surprising: Hit Dexter 2.0 predicts approximately 13% [26%] 
of approved drugs as promiscuous and 6% [12%] as highly promiscuous (Figure 10E), which is 
generally even higher than the rates predicted for aggregators. Several approved drugs are known 
to form colloidal aggregates under specific assay conditions. However, a substantial part of the 
predicted frequent hitter behavior is likely linked to true promiscuity. Given the challenges 
involved in designing selective small molecules, this is not only plausible but also forms the 
basis for drug repurposing and polypharmacology. Note that the percentages of compounds 
predicted as (highly) promiscuous differ substantially between the (processed) approved drugs 
data set and the respective subset of compounds well-represented by the training data. These 
differences are plausible because of substantial differences in the composition of the two data 
sets: the processed approved drugs data set consists of around one thousand compounds, and the 
subset consists of only approximately three hundred compounds. 
Interestingly, the distributions of class probabilities for approved drugs are even slightly steeper 
than those calculated for potential PAINS (Figure 10F). This supports the case that compounds 
matching PAINS patterns are not necessarily frequent hitters. 
 
 
Figure 10. Distribution of class probabilities predicted with classifiers derived from PSA and 
CDRA data for (A) dark chemical matter, (B) known aggregators, (C) screening compounds 
from the Enamine HTS Collection, (D) the ChEMBL database, (E) approved drugs from 
DrugBank and (F) subset of compounds of the Enamine HTS collection that match at least one 
PAINS pattern. 
 
Last but not least we utilized Hit Dexter 2.0 to predict the promiscuity of 208k natural products. 
Natural products can be challenging to screen in vitro and it is known that several classes of 
natural products are prone to interfere with biochemical assays for different reasons.41 This is 
reflected by the predictions of Hit Dexter 2.0. The class probability distribution curves (in 
particular of those of the P-NP classifiers) show a steeper increase than for any other investigated 
data set (Figure 11A). Particularly noticeable is the high percentage of (highly) promiscuous 
compounds among flavonoids (the natural product classes were assigned with an automated 
approach presented previously),40 with approximately 65% [73%] of all flavonoids predicted as 
promiscuous and 20% [31%] as highly promiscuous (Figure 10B). Among the investigated 
flavonoid subclasses (anthocyanidins, chalcones, flavandioles, flavanoles, flavanones, 
flavanonoles, flavones, flavonoles and isoflavones), chalcones showed the highest rates of highly 
promiscuous (~42% [50%]) and promiscuous (~85% [86%]) compounds (Figure 11C; note that 
anthocyanidins are not represented in sufficient numbers in the data set that would allow to draw 
definite conclusions on their hit rates in assays). In contrast to the observations with flavonoids, 
Hit Dexter 2.0 reports less than 2% [9%] of all basic alkaloids (see ref 40 for the exact 
definition) as highly promiscuous and less than 6% [21%] as promiscuous (Figure 10D; note that 
the subset of compounds covered by the training data according to the above-mentioned criterion 
is just 10%). 
Flavonoids have been reported in the literature to exhibit bioactivity on a large number of 
different proteins.41 For example, according to a recent analysis,41 by the year 2016 more than 
680 distinct activities had been reported for quercetin, which is one of the most widely 
distributed flavonoids in nature but also a known aggregator and PAINS. For this particular 
flavonoid, PubChem Bioassay currently lists conclusive testing results of more than one 
thousand distinct assays, with quercetin reported as active in close to one out of two of these 
assay outcomes.  
Whereas the health-promoting benefits of quercetin and other flavonoids are undisputed, it is 
reasonable to assume that many of the recorded activities are likely a result of assay interference. 
It is important to reemphasize at this occasion that the potential of a compound to interfere with 
assays does not per se lower its value as a bioactive compound, but it may make the rational 
optimization of its activity a difficult or, in some cases, even impossible task. 
 
 
Figure 11. Distribution of class probabilities obtained with classifiers trained on PSA and CDRA 
data for (A) all natural products, (B) flavonoids, (C) chalcones and (D) basic alkaloids. 
 
Exploration of the Badapple Data Sets with Hit Dexter 2.0 
In contrast to Hit Dexter 2.0, which is trained on complete molecular structures, the Badapple 
model is derived from molecular scaffolds, each of which was assigned a promiscuity score. In 
order explore to what extent predictions of Hit Dexter 2.0 based on molecular scaffolds are in 
agreement with Badapple (and the underlying data sets), we compiled sets of 142 468 non-
promiscuous scaffolds ("BADAPPLE_NP"), 610 promiscuous scaffolds ("BADAPPLE_P") and 
231 highly promiscuous scaffolds ("BADAPPLE_HP") from the Badapple data sets (published 
in ref 16).  
As shown in Figure 12, Hit Dexter 2.0 is able to recognize compound promiscuity based on 
molecular scaffolds even though it was trained on complete molecular structures. Hit Dexter 2.0 
correctly predicted the vast majority (91 to 99% [90 to 99%]) of non-promiscuous scaffolds 
(Figure 12A). Both P-NP classifiers detected about 57% [72%] of all promiscuous scaffolds as 
such (Figure 12B), and both HP-NP classifiers predicted around 50% [79%] of the highly 
promiscuous scaffolds as such (Figure 12C). This can be considered a good agreement for two 
reasons: First, Hit Dexter 2.0 and Badapple use distinct thresholds for labeling compounds, and 
second, the BADAPPLE_HP and BADAPPLE_P data sets are small in size and contain only 300 
and 100 scaffolds (after preprocessing and removal of duplicates), respectively. 
 
 
Figure 12. Hit Dexter 2.0 predictions of scaffold promiscuity for the (A) BADAPPLE_NP, (B) 
BADAPPLE_P and (C) BADAPPLE_HP data sets. 
 
Comparison of the PSA and CDRA Models 
As shown in the previous section, the overall behavior and performance of the PSA and CDRA 
models are comparable. In particular, the numbers of compounds assigned by the different 
models to one of the three promiscuity classes are similar. One interesting aspect to investigate is 
the agreement between predictions of the PSA and CDRA classifiers. Table 5 provides an 
overview of this for each of the above-mentioned data sets. Taking the Approved Drugs subset of 
DrugBank as an example, the PSA and CDRA models predicted 48 compounds (~5%) and 58 
compounds (~6%) of this data set as highly promiscuous. The agreement between both 
predictions (defined as the fraction of compounds predicted as highly promiscuous by both 
classifiers as compared to those predicted as highly promiscuous by either classifier) was 
approximately 40%. Given the fact that only a small number of compounds was predicted as 
highly promiscuous, this can be considered a good agreement. For the BADAPPLE_HP data set, 
which consists entirely of highly promiscuous scaffolds, the agreement between the predictions 
made by the PSA HP-NP and CDRA HP-NP classifiers was 75%. Nevertheless, both classifiers 
have different sensitivity and for this reason the use of both predictors in parallel is 
recommended. 
Hit Dexter 2.0 Web Service 
The previously introduced Hit Dexter web service17 was extended substantially. In addition to all 
models described in this work, we also implemented capabilities to predict aggregators and DCM 
based on molecular similarity, and to flag nuisance and undesired compounds based on several 
established collections of SMARTS patterns:  
● The “hard filters” rule set developed at Glaxo Wellcome,42 consisting of 55 patterns of 
undesired functional groups.  
● A rule set developed at the University of Dundee,43 consisting of 105 patterns of 
unwanted functional groups and substructures that likely cause interference with HTS 
assays. 
● The “HTS deck filters” rule set developed at Bristol-Meyers Squibb,44 consisting of 180 
patterns of unwanted functional groups derived from intuition and experience. 
● The SureChEMBL rule set of ToxAlert,45 consisting of 166 patterns of toxicophores. 
● The “excluded functionality filters” rule set of the NIH Molecular Libraries Small 
Molecule Repository,46 consisting of 116 patterns for removing unwanted functional 
groups. 
● The “Lint” rule set developed at Pfizer,47 consisting 57 patterns of problematic functional 
groups during drug optimization. 
● The PAINS set of substructures linked to assay interference,7 consisting of 480 patterns. 
Note that the original PAINS patterns were encoded by Sybyl line notation7 whereas the 
Hit Dexter 2.0 web service utilizes SMARTS patterns in combination with the 
substructure search implemented in RDKit.48 This may lead to differing results in some 
cases. 
● A set of 28 substructures derived from undesirable compounds. This is a subset of rules 
recently introduced by investigators from GlaxoSmithKline. The 28 substructures are 
listed in Table S2 of ref 23 (value “remove” in column “GSK Recommendation”). 
Search queries can either be sketched with the JSME Molecule Editor,49 pasted as individual 
SMILES or uploaded as a list of SMILES. Predictions are presented as a heat map (Figure 13) 
and include the results from all the machine learning models, similarity-based and rule-based 
approaches. Importantly, also the distance to the nearest neighbor in the training data is reported, 
which gives an indication of the reliability of predictions. A column with comments summarizes 
the conclusions that may be drawn from the predictions. We believe that these comments will be 
helpful in particular to occasional users of Hit Dexter 2.0. 
The processing of a single compound takes few seconds. Predictions for 1000 compounds take 
approximately 4 hours. The authors plan to increase the capacity of the web service should the 
need arise. 
 




In this work we report on the second generation of machine learning models for the prediction of 
frequent hitters independent of the underlying physicochemical mechanisms, including the 
binding of compounds based on "privileged scaffolds" or of “master key compounds” to multiple 
binding sites. These models are, among others, accessible via the Hit Dexter 2.0 web service.19 
In addition to a number of refinements of the data preparation and modeling strategy, substantial 
improvements presented in this work include the implementation of a protein clustering method 
in order to avoid an overrepresentation of structurally and functionally related proteins in the 
training data, and the utilization of PSA data, in addition to CDRA data, for machine learning. 
During comprehensive tests on independent data, models based on either PSA or CDRA data 
were shown to predict frequent hitters with high accuracy and robustness. While predictions 
from both model types were generally in good agreement, the parallel use of both types of 
classifiers can support the interpretation of results and is recommended. 
Hit Dexter 2.0 was used for profiling compounds with specific biological and physicochemical 
properties, such as dark chemical matter, aggregators, compounds from a high-throughput 
screening library, drug-like compounds, approved drugs, potential PAINS and natural products. 
The predictions obtained with Hit Dexter 2.0 confirm common observations and knowledge but 
also led to some less anticipated observations, such as the high fraction of frequent hitters 
predicted among approved drugs. A further encouraging observation made was the good 
agreement between predictions of Hit Dexter 2.0 and the Badapple data sets of molecular 
scaffolds and their observed promiscuity. 
Since its initial launch in late 2017, the Hit Dexter web service has evolved from a small web 
presence with rudimentary features into a one-stop shop for the interrogation of compounds 
regarding their likelihood to exhibit frequent hitter behavior and/or interfere with biochemical 
assays, and their general desirability in the context of drug discovery. More specifically, the new 
Hit Dexter 2.0 web service provides user-friendly access to machine learning approaches for the 
prediction of compound promiscuity, similarity-based methods for the prediction of aggregators 
and dark chemical matter, and a comprehensive collection of established and new rule sets for 
flagging frequent hitters and compounds with undesired substructures. 
We believe that Hit Dexter 2.0 will enable investigators to make better-informed decisions 
during hit triage and follow-up. However, the models should not be used as the sole basis for the 
acceptance or rejection of hits. 
METHODS 
Data sets 
Activity data measured for chemical substances (substance type = ”chemical”) on single protein 
targets (target = ”single” and target type = ”Protein Targets”) in 932 primary screening assays 
(screening stage = ”primary screening”) and 2266 confirmatory dose-response assays (screening 
stage = ”confirmatory, dose-response”) were separately downloaded from the PubChem 
Bioassay database21,22,50 via the PUG REST interface.51 The download of BioAssay record AID 
1224865 failed permanently and was therefore not considered in this work. The SMILES 
notations for all 803 898 compounds of the primary screening assays (PSAs) and all 468 260 
compounds of the confirmatory dose-response assays (CDRAs) were retrieved via the PubChem 
Identifier Exchange Service.52 Salt components, compounds with unsupported elements, and 
conflicting bioactivity data were identified and removed following the procedure described in ref 
17. Also compounds with a molecular weight below 200 Da and above 900 Da were removed. In 
addition, all molecular structures were neutralized and tautomers merged using the “canonalize” 
method implemented in the “tautomer” class of MolVS.53 Subsequently, duplicate compounds 
were removed based on identical SMILES. In order to ensure the consistency of predictions, 
compounds with identical Morgan2 fingerprints and differing promiscuity labels (e.g. 
stereoisomers) were removed from the training sets. This concerned a total of 1945 compounds 
for the PSA and 2 825 compounds for the CDRA training sets. For any compounds with identical 
Morgan2 fingerprints only one instance was kept in the training sets. 
For each PubChem Bioassay record the unique identifier for genes of the NCBI Protein 
database54 (“gene identifier”, GI) was obtained via the PubChem PUG REST interface. In total, 
429 and 712 unique GIs were retrieved for the PSA and CDRA records, respectively. 
Subsequently, using these GIs, the protein sequences of all proteins of interest were downloaded 
in FASTA file format from the NCBI Protein database. Clustering of all protein sequences with 
cd-hit 55 (sequence identity = 60%; tolerance = 3) resulted in 388 and 537 protein clusters for the 
PSA and CDRA records, respectively. 
For model development, each data set was split randomly into an external test set (10%) and a 
training set (90%) with the “train_test_split” method of the “model_selection” module of scikit-
learn (version: 0.19.1).35 Only the training set was used for model selection. Initial experiments 
for selecting the most suitable machine learning algorithm and descriptor sets were performed 
with default parameters for ETCs and RFCs, except for the number of estimators, which was set 
to 50, the class weight, which was set to “balanced”, and bootstrapping, which was disabled. 
Default parameters were used for all meta classifiers (with ETCs and RFCs parameterized as 
described above). Stratified splitting was performed as part of cross-validation. 
All data sets used to explore and determine the performance of Hit Dexter 2.0 were prepared and 
filtered according to identical protocol as outlined for the training data.  
The Badapple data sets were compiled from the original source16 by merging scaffolds with 
identical SMILES and removing any instances with contradicting promiscuity labels. Scaffolds 
assigned a pScore above 300 were included in the BADAPPLE_HP data set, scaffolds assigned a 
pScore between 100 and 299 were included in the BADAPPLE_P data set, and scaffolds 
assigned a pScore between 0 and 99 were included in the BADAPPLE_NP data set. 
Hardware and Software 
All calculations are performed on Linux workstations running openSUSE 42.2 and equipped 
with Intel i5 processors (3.2 GHz) and 16GB of main memory. 
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ABBREVIATIONS 
ATR, active to tested ratio 
AUC, area under the ROC curve 
CDRA, confirmatory dose-response assay 
DCM, dark chemical matter 
ETC, extra tree classifier 
HP, highly promiscuous 
HTS, high-throughput screening 
MCC, Matthews correlation coefficient 
MOE, Molecular Operating Environment 
NP, non-promiscuous 
P, promiscuous 
PAINS, pan-assay interference compounds 
PCA, principal component analysis 
PSA, primary screen assay 
RFC, random forest classifier 
ROC, receiver operating characteristic 
SMARTS, SMILES arbitrary target specification 
SMILES, simplified molecular input line entry specification 
SMOTE, synthetic minority oversampling technique 
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